Agentix Corp.
AGTX evidence brief
What we can confirm
- BioSniper Score:
- 3.0 / 10
- Market Cap:
- $801K
- Lead Asset:
- agtx-2003 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for AGTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AGTX
Agentix Corp. (AGTX) is a clinical-stage biopharmaceutical company developing synthetic and natural cannabinoid therapeutics for unmet medical needs, currently facing severe financial constraints and deep negative equity.
Key risk: Extreme negative equity
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$801K
Cash Runway
—
Lead Asset
agtx-2003 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Agentix Corp..
Agentix Corp. (AGTX) is a clinical-stage biopharmaceutical company developing synthetic and natural cannabinoid therapeutics for unmet medical needs, currently facing severe financial constraints and deep negative equity.
- The company focuses on developing synthetic and natural cannabinoid therapeutics targeting areas like inflammatory disease, progressive lung disease, and ischemic reperfusion injury [sec · filed 2020-09-17].
- As of the latest structured financial data (2026-06-30), Agentix reported net income of -$0.1M and shareholders' equity of -$3.7M [sec].
- The company's cash position was negligible ($93) as of early September 2020, and total liabilities ($125,878) far exceeded total assets ($93) in the same period [sec · filed 2020-09-17].
- Agentix has never submitted a New Drug Application (NDA) to the FDA and faces significant regulatory hurdles for its product candidates [sec · filed 2020-09-17].
- The company acknowledges a limited operating history and substantial uncertainties in implementing its business plan, manufacturing, and raising capital [sec · filed 2020-09-17].
What works
- Agentix targets a multibillion-dollar global biopharmaceutical market with its cannabinoid therapeutic platform [sec · filed 2020-09-17].
- The company's strategy includes developing health and wellness products using a proprietary 'cellular biocomplex' nano-technology delivery system [sec · filed 2020-09-15].
What to weigh
- Agentix has a negative shareholders' equity of -$3.7M as of 2026-06-30, indicating severe financial distress and potential inability to sustain operations [sec].
- The company had negligible cash ($93) and total assets ($93) versus massive liabilities ($125,355) in September 2020, showing extreme insolvency [sec · filed 2020-09-17].
- Agentix has no revenue-generating products, no NDA submissions, and faces high risk of failure in product development and regulatory approval [sec · filed 2020-09-17].
- The company warns it may need to reduce activities or cease operations if it cannot commercialize products or raise additional capital [sec · filed 2020-09-15].
From the filings
Quoted directly from source documents.
Focus on cannabinoid therapeutics for unmet medical needs
“develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs”
SEC filings · September 17, 2020
No NDA has ever been submitted
“We have never submitted an NDA to the FDA or comparable applications to other regulatory authorities.”
SEC filings · September 17, 2020
High risk of business failure
“If we are unsuccessful in commercializing our products or raising capital, we may need to reduce activities, curtail or cease operations.”
SEC filings · September 15, 2020
Risks & what to watch (3)›
Key risks
- Extreme negative equity — Shareholders' equity of -$3.7M and negative cash balance indicate severe financial distress and risk of bankruptcy [sec].
- No revenue or approved products — No NDA submitted, no commercial sales; revenue generation depends on uncertain product development and regulatory approvals [sec · filed 2020-09-17].
- Inability to raise capital — Extremely low cash and high liabilities risk further capital raising failure, potentially forcing curtailment of operations [sec · filed 2020-09-15].
What to watch
- Whether the company can secure additional funding to continue operations (no recent capital raises noted) [sec · filed 2020-09-15].
- Progress of potential regulatory filings for its cannabinoid therapeutic candidates (no NDA has been filed historically) [sec · filed 2020-09-17].
- Any clinical trial updates or partnerships that could provide revenue or milestone payments [sec · filed 2020-09-17].
Sources: SEC filings · Generated September 11, 2026 · How we verify sources →
Run Agentix Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Agentix Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
OCF -$26K · Net income -$118K
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Agentix Corp.?
Agentix Corp. (AGTX) is a clinical-stage biopharmaceutical company developing synthetic and natural cannabinoid therapeutics for unmet medical needs, currently facing severe financial constraints and deep negative equity.
What is Agentix Corp.'s lead drug candidate?
Agentix Corp.'s most advanced tracked candidate is agtx-2003 (Preclinical) for obesity and non-alcoholic fatty liver disease (NAFLD).
Who is the CEO of Agentix Corp.?
Mr. Riazul Huda is the chief executive officer of Agentix Corp. (AGTX).
Where is Agentix Corp. headquartered?
Agentix Corp. (AGTX) is headquartered in Dana Point, CA, United States.
What therapeutic areas does Agentix Corp. focus on?
Agentix Corp. develops therapies across Metabolic, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.